Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of TransCode Therapeutics, Inc. (NASDAQ:RNAZ), it sends a ...

PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON, Feb. 6, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed ...

TransCode Therapeutics, Inc., the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced that the first patient in Cohort 4 of its phase I clinical trial ...

Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter TransCode Therapeutics ( (RNAZ)) has ...

BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap RNA oncology company with a market capitalization of $6.22 ...